---
document_datetime: 2025-12-02 06:07:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/atazanavir-mylan.html
document_name: atazanavir-mylan.html
version: success
processing_time: 0.1271844
conversion_datetime: 2025-12-26 10:33:20.534722
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Atazanavir Viatris (previously Atazanavir Mylan)

[RSS](/en/individual-human-medicine.xml/65876)

##### Authorised

This medicine is authorised for use in the European Union

atazanavir Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Atazanavir Viatris (previously Atazanavir Mylan)](#news-on)
- [More information on Atazanavir Mylan](#more-information-on-atazanavir-mylan-1127)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Atazanavir Viatris is an HIV medicine used to treat patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immunodeficiency syndrome (AIDS). It is used together with low-dose ritonavir and other antiviral medicines to treat patients aged 6 years and over.

Doctors should prescribe Atazanavir Viatris only after they have looked at which medicines the patient has taken and carried out tests to establish that the virus is likely to respond to Atazanavir Viatris. The medicine is not expected to work in patients in whom many medicines in the same class as Atazanavir Viatris (protease inhibitors) do not work.

Atazanavir Viatris contains the active substance atazanavir and is a 'generic medicine'. This means that Atazanavir Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Atazanavir Viatris is Reyataz. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Atazanavir Viatris used?

Atazanavir Viatris is available as capsules. It can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection.

For adults, the recommended dose is 300 mg once a day. In younger patients, the dose of Atazanavir Viatris depends on body weight. Each dose must be taken with food.

Atazanavir Viatris is normally given with ritonavir to boost its action but doctors can consider stopping ritonavir in adults in some specific situations.

For more information about using Atazanavir Viatris, see the package leaflet or contract your doctor or pharmacist.

## How does Atazanavir Viatris work?

The active substance in Atazanavir Viatris, atazanavir, is a protease inhibitor. It blocks an enzyme called protease, which is needed for the virus to multiply. Blocking the enzyme prevents the virus from multiplying, slowing down the spread of infection. A small dose of another medicine, ritonavir, is normally given at the same time as a 'booster'. Ritonavir slows down the break-down of atazanavir, increasing the levels of atazanavir in the blood. This allows a lower dose of atazanavir to be used for the same antiviral effect. Atazanavir Viatris, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level. Atazanavir Viatris does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.

## How has Atazanavir Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out in the reference medicine, Reyataz, and do not need to be repeated for Atazanavir Viatris.

As for every medicine, the company provided studies on the quality of Atazanavir Viatris. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Atazanavir Viatris?

Because Atazanavir Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Atazanavir Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Atazanavir Viatris has been shown to have comparable quality and to be bioequivalent to Reyataz. Therefore, the Agency's view was that, as for Reyataz, the benefits of Atazanavir Viatris outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Atazanavir Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Atazanavir Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Reyataz also apply to Atazanavir Viatris where appropriate.

As for all medicines, data on the use of Atazanavir Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Atazanavir Viatris

Atazanavir Mylan received a marketing authorisation valid throughout the EU on 22 August 2016.

The name of the medicine was changed to Atazanavir Viatris on 29 July 2024.

Atazanavir Mylan : EPAR - Medicine overview

Reference Number: EMA/244864/2024

English (EN) (145.06 KB - PDF)

**First published:** 31/01/2017

**Last updated:** 18/06/2025

[View](/en/documents/overview/atazanavir-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-901)

български (BG) (160.88 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/bg/documents/overview/atazanavir-mylan-epar-medicine-overview_bg.pdf)

español (ES) (146.54 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/es/documents/overview/atazanavir-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (133.31 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/cs/documents/overview/atazanavir-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (145.79 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/da/documents/overview/atazanavir-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (140.32 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/de/documents/overview/atazanavir-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (133.48 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/et/documents/overview/atazanavir-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (171.47 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/el/documents/overview/atazanavir-mylan-epar-medicine-overview_el.pdf)

français (FR) (148.02 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/fr/documents/overview/atazanavir-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (165.92 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/hr/documents/overview/atazanavir-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (135.72 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/it/documents/overview/atazanavir-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (184.33 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/lv/documents/overview/atazanavir-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (168.09 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/lt/documents/overview/atazanavir-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (168.75 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/hu/documents/overview/atazanavir-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (170.92 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/mt/documents/overview/atazanavir-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (147.11 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/nl/documents/overview/atazanavir-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (173.62 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/pl/documents/overview/atazanavir-mylan-epar-medicine-overview_pl.pdf)

português (PT) (147.11 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/pt/documents/overview/atazanavir-mylan-epar-medicine-overview_pt.pdf)

română (RO) (167.46 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/ro/documents/overview/atazanavir-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (169.49 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/sk/documents/overview/atazanavir-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (165.31 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/sl/documents/overview/atazanavir-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (133.47 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/fi/documents/overview/atazanavir-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (134.76 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

18/06/2025

[View](/sv/documents/overview/atazanavir-mylan-epar-medicine-overview_sv.pdf)

## Product information

Atazanavir Viatris : EPAR - Product Information

English (EN) (629.84 KB - PDF)

**First published:** 31/01/2017

**Last updated:** 14/05/2025

[View](/en/documents/product-information/atazanavir-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-140)

български (BG) (963.52 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/bg/documents/product-information/atazanavir-viatris-epar-product-information_bg.pdf)

español (ES) (630.11 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/es/documents/product-information/atazanavir-viatris-epar-product-information_es.pdf)

čeština (CS) (799.51 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/cs/documents/product-information/atazanavir-viatris-epar-product-information_cs.pdf)

dansk (DA) (753.98 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/da/documents/product-information/atazanavir-viatris-epar-product-information_da.pdf)

Deutsch (DE) (783.77 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/de/documents/product-information/atazanavir-viatris-epar-product-information_de.pdf)

eesti keel (ET) (722.92 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/et/documents/product-information/atazanavir-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (931.94 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/el/documents/product-information/atazanavir-viatris-epar-product-information_el.pdf)

français (FR) (794.55 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/fr/documents/product-information/atazanavir-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (824.35 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/hr/documents/product-information/atazanavir-viatris-epar-product-information_hr.pdf)

íslenska (IS) (714.6 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/is/documents/product-information/atazanavir-viatris-epar-product-information_is.pdf)

italiano (IT) (573.85 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/it/documents/product-information/atazanavir-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (831.96 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/lv/documents/product-information/atazanavir-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (898.4 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/lt/documents/product-information/atazanavir-viatris-epar-product-information_lt.pdf)

magyar (HU) (848.77 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/hu/documents/product-information/atazanavir-viatris-epar-product-information_hu.pdf)

Malti (MT) (875.26 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/mt/documents/product-information/atazanavir-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (799.74 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/nl/documents/product-information/atazanavir-viatris-epar-product-information_nl.pdf)

norsk (NO) (726.73 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/no/documents/product-information/atazanavir-viatris-epar-product-information_no.pdf)

polski (PL) (873.84 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/pl/documents/product-information/atazanavir-viatris-epar-product-information_pl.pdf)

português (PT) (409.27 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/pt/documents/product-information/atazanavir-viatris-epar-product-information_pt.pdf)

română (RO) (840.61 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/ro/documents/product-information/atazanavir-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (877.17 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/sk/documents/product-information/atazanavir-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (835.66 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/sl/documents/product-information/atazanavir-viatris-epar-product-information_sl.pdf)

Suomi (FI) (723.24 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/fi/documents/product-information/atazanavir-viatris-epar-product-information_fi.pdf)

svenska (SV) (748.26 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

14/05/2025

[View](/sv/documents/product-information/atazanavir-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000268126 14/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Atazanavir Viatris (previously Atazanavir Mylan) : EPAR - All Authorised presentations

English (EN) (47.81 KB - PDF)

**First published:** 31/01/2017

**Last updated:** 24/05/2025

[View](/en/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-371)

български (BG) (53.63 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/bg/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.92 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/es/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (49.81 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/cs/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.17 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/da/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (43.11 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/de/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.7 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/et/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.02 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/el/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (15.25 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/fr/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (71.34 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/hr/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.96 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/is/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.68 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/it/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (60.44 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/lv/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.63 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/lt/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.61 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/hu/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.96 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/mt/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.65 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/nl/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (35.61 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/no/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.5 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/pl/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (9.86 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/pt/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (48.06 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/ro/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.28 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/sk/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.33 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/sl/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (54.37 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/fi/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.22 KB - PDF)

**First published:**

31/01/2017

**Last updated:**

24/05/2025

[View](/sv/documents/all-authorised-presentations/atazanavir-viatris-previously-atazanavir-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Atazanavir Viatris (previously Atazanavir Mylan) Active substance atazanavir (as sulfate) International non-proprietary name (INN) or common name atazanavir Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AE08

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Atazanavir Viatris, co-administered with low dose ritonavir, is indicated for the treatment of HIV 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations). There are very limited data available from children aged 6 to less than 18 years. The choice of Atazanavir  Viatrisin treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient's treatment history.

## Authorisation details

EMA product number EMEA/H/C/004048

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Dublin 15 Ireland

Opinion adopted 23/06/2016 Marketing authorisation issued 22/08/2016 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Atazanavir Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (152.32 KB - PDF)

**First published:** 24/05/2024

**Last updated:** 14/05/2025

[View](/en/documents/procedural-steps-after/atazanavir-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Atazanavir Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (146.21 KB - PDF)

**First published:** 13/07/2017

**Last updated:** 21/02/2024

[View](/en/documents/procedural-steps-after/atazanavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Atazanavir Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/503216/2016

English (EN) (402.71 KB - PDF)

**First published:** 31/01/2017

**Last updated:** 31/01/2017

[View](/en/documents/assessment-report/atazanavir-mylan-epar-public-assessment-report_en.pdf)

#### News on Atazanavir Viatris (previously Atazanavir Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

#### More information on Atazanavir Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/06/2025

## Share this page

[Back to top](#main-content)